Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT02638805

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02638805
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02638805. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2017-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
ITCA 650 Osmotic Mini Pump 20/60 mcg/day
Intervention (Drug)
ITCA 650 Osmotic Mini Pump 60 mcg/day
Intervention (Drug)
Metformin
Intervention (Drug)
Liraglutide
Lead sponsor
Intarcia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02638805
Content hash
12f0d8d8b0cb518c868e9b48f144716694917b3d9c78d099a530038489e3675c